The epi-retinal implant has 150 electrodes and a bio-inspired camera intended for patients who have lost sight due to retinitis pigmentosa.
The French company said the implantation and activation was performed in September by principal investigator Dr. Mahi Muqit at Moorfields Eye Hospital. The procedure was done as a part of Pixium’s ongoing, multi-center clinical trial to evaluate the efficacy of IRIS II as a treatment to compensate for blindness and provide greater autonomy for patients.
“The first IRIS II implant in UK at the prestigious Moorfields hospital, is part of the company’s strategy to continue to expand its presence across centres of excellence in Europe,” CEO Khalid Ishaque said in prepared remarks. “Pixium Vision is dedicated to conceive, develop and bring meaningful bionic vision innovations to surgeons, which shall enable them to treat patients who have lost sight to retinal dystrophies.”
“This first IRIS II retinal implant in the UK was successfully completed for the 73 year old retinitis pigmentosa patient. The 150 electrode implant with its explantable design, may become an innovative option for the retinal surgeons. Participation in this European clinical trial allows us to evaluate the new system,” Dr. Muqit added. “The patient’s system was activated and he reported first perception of light. Per clinical protocol, the patient will now enter training and re-adaptation to learn how to interpret the new light signals.”